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Low rate of calreticulin mutations in refractory anaemia with ring
sideroblasts and marked thrombocytosis
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Refractory anaemia with ring sideroblasts (RARS) and marked
thrombocytosis (RARS-T) was proposed in the World Health
Organisation 2001 classiﬁcation of tumours of haematopoietic
and lymphoid tissues and retained as a provisional entity in the
2008 version.1 RARS-T is characterised by a high rate of JAK2V617F
mutations2–4 or the presence of mutations in exon 10 of MPL
(myeloproliferative leukaemia).5,6 The existence of RARS-T as an
entity independent from RARS and essential thrombocythemia
(ET) was a matter of debate, as certain specialists favoured the
hypothesis that RARS-T was a form of ET with 415% of ring
sideroblasts in the bone marrow, whereas others thought that
RARS-T is derived from RARS with secondary thrombocytosis
developing through the acquisition of the JAK2V617F mutation.
We recently demonstrated that RARS-T differed from RARS and
ET from a clinical, biological and prognostic point of view.4 The
presence of high rates of splicing factor 3B subunit 1 (SF3B1)
mutations in RARS-T and the absence of these mutations in ET
strengthened the hypothesis that RARS-T was a distinct entity.7–9
However, the myeloproliferative features of RARS-T are not totally
explained by JAK2V617F and MPLW515L mutations, as these account
for only 50% and 1% of RARS-T, respectively. The question remains
about other causative mutations responsible for the myeloproli-
ferative part of RARS-T. The challenge is the same in myeloproli-
ferative neoplasms (MPN), as 50–60% of ET and primary
myeloﬁbrosis (PMF) do not present with any JAK2 orMPLmutations.
The recent discovery of a high rate of calreticulin (CALR)
mutations in JAK2-non-mutated MPNs was a great step towards
better understanding of the molecular pattern of these diseases.
Mutations in exon 9 of CALR have been reported as mutually
exclusive of JAK2 and MPL mutations, and found in 67–71% of ET
and 56–88% of PMF with wild-type JAK2 or MPL.10,11 These
mutations are insertions or deletions leading to a frameshift
responsible for modifying the C-terminal part of the protein.
Following these modiﬁcations, the C-terminal part of the protein
becomes positively charged and the reticulum targeting KDEL
sequence is abrogated, which disturbs its cellular localisation.
Up to now, CALR mutations have only been explored in small
RARS-T cohorts, with a mutation frequency ranging from 0 to
12.5%.10,11 The purpose of our study was to analyse the frequency
of CALR mutations in a large RARS-T cohort in order to determine
whether CALR mutations may also be responsible for
thrombocytosis in this disease. We therefore analysed a large
cohort of 95 RARS-T patients, with 29 RARS as the control.
According to the WHO 2008 classiﬁcation, patients are
diagnosed with RARS-T if they fulﬁl the following criteria:
i) anaemia (haemoglobin level o125 g/l for females and
o135 g/l for males) with erythroid dysplasia and 415% ring
sideroblasts; ii) thrombocytosis with 4450 109 platelets/l; iii)
o5% blast cells in the bone marrow; iv) presence of large atypical
megakaryocytes similar to those observed in BCR-ABL1-negative
MPN; v) no secondary cause of ring sideroblasts; and vi)
no karyotype abnormalities such as del(5q), t(3;3)(q21;q26)
or inv(3)(q21q26).1 One hundred and twenty-four samples
including 95 RARS-T and 29 RARS from seven European centres
in three European countries were collected and tested. This cohort
has been published previously.4,9
For each patient, demographic (gender and age at diagnosis) and
biological data (blood cell count, bone marrow exploration, ring
sideroblasts, karyotype and molecular explorations) were collected.
The SF3B1 mutations were analysed with a sensitive next-
generation amplicon deep-sequencing assay (454 Life Sciences,
Branford, CT, USA) with a median coverage of 500 reads. This
approach was able to detect mutations with a sensitivity below 1%.9
The JAK2V617F mutation was analysed by allele-speciﬁc real-time
PCR to estimate the allele burden according to the method
published by Lippert et al.12 with a sensitivity of 1%. JAK2 exon 12
analysis was performed according to the method by Schnittger
et al.13 and the MPLW515 mutations were analysed by high-
resolution melting curve analyses followed by Sanger sequencing
if positive, as previously published by Schnittger et al.14
The CALR exon 9 mutations were screened by fragment analysis
and Sanger sequencing according to the method by Klampﬂ et al.10
Approval for the study was obtained from the ethics committee
of each institution and the procedures were carried out in
accordance with the Helsinki Declaration of 1975, as revised
in 2000.
A total of 124 cases with 95 RARS-T and 29 RARS (including 62
males and 62 females) were recorded in the study, which is, to our
best knowledge, the largest series of myelodysplastic syndromes
with ring sideroblasts (MDS-RS) studied for CALR mutations. The
median age at diagnosis was 74 years and 73 years for the RARS-T
and RARS cohort, respectively (Table 1). A karyotype was available
in 112 cases (87 RARS-T and 25 RARS). Seventy-ﬁve (86.2%) RARS-T
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patients carried a normal karyotype, whereas 12 (13.8%) patients
showed aberrant karyotypes. The rates in RARS-T and RARS
patients were comparable.
An SF3B1 mutation was noted in 24 (82.7%) RARS and 83
(88.3%) RARS-T conﬁrming that this mutation is highly repre-
sented in MDS-RS.
A JAK2V617F mutation was noted in 47 of the 95 RARS-T patients
(49.4%) but in no RARS patients. The JAK2V617F allele burden was
very heterogeneous with a median of 33.3% (range: 1–92%). No
JAK2 exon 12 mutation (19 tested) was observed, whereas only
one MPLW515L mutation was noted in a patient with RARS-T
(88 tested; Table 1 and Figure 1).
A CALR mutation was noted in only one (1%) RARS-T and one
(3.4%) RARS patient. The CALR mutation found in the RARS-T
patient was a 10-bp (1129–1138) deletion located in exon 9.
Surprisingly, this patient also presented a JAK2V617F mutation with
a low allele burden (4%) and an SF3B1 mutation. The mutational
status of this patient was conﬁrmed by two independent
laboratories on two different DNA samples. This patient is a
73-year-old women diagnosed in 2010. At diagnosis, her blood cell
count revealed anaemia (haemoglobin 106 g/l) and a marked
thrombocytosis (992 109 platelets/l). She is currently under
cytoreductive and antiplatelet treatment and her last blood count
revealed a mild anaemia (haemoglobin 104 g/l) and a platelet
count lowered to 600 109/l.
Among the 29 RARS, we also identiﬁed a single case with a
CALR mutation. This unique CALR-positive RARS case was a 70-
year-old man who had thrombocytopenia and carried an SF3B1
mutation.
In the present study on JAK2 and MPL mutations, our results are
in accordance with the usually reported prevalence of JAK2V617F in
half of RARS-T and the low frequency of MPL mutations.2–6
Recent publications have reported a variable frequency of CALR
mutations in MDS-RS: 0/6 to 3/24 in RARS-T, 3/27 in RARS and 0/3 in
refractory cytopenia with multilineage dysplasia and ring side-
roblasts.10,11 However, these results were obtained in small series of
patients, thus leading to potential biases. Of note, a high proportion
(12.5%) of CALR mutations in RARS-T in one series of 24 patients
contrasts with our results where only one positive case in 95 patients
was noted. In particular, one of the three previously reported CALR-
positive RARS-T cases did not harbour the SF3B1 mutation, a
frequent hallmark of RARS-T. Moreover, in this series, the frequency
of the SF3B1 mutation was much lower than in ours (66% vs 88%)
suggesting that this CALR-positive SF3B1-negative RARS-T case could
be MPN rather than RARS-T, owing to the difﬁculty of asserting the
diagnosis in some cases. Finally, the low rate of CALR mutations in
the present RARS-T series is similar (0–3%) to that reported in
chronic myelomonocytic leukaemia, another MDS/MPN.10,11
Table 1. Demographic and biological characteristics of RARS-T and
RARS patients
RARS-T patients RARS patients
n 95 29
Male (%) 45.2 65.5
Age at diagnosis (years)
Median 74.0 73.0
Range 44.4–88.1 48.4–93.0
20–50 (n) 4 2
50–70 (n) 30 8
470 (n) 61 19
WBC ( 109/l)
Median 7.6 5.5
Range 2.1–60 1.9–17.3
Hb (g/l)
Median 9.6 9.1
Range 5.1–12.9 6.9–12.8
Platelets ( 109/l)
Median 655 274
Range 455–1500 61–444
450–600 (n) 45
4600 (n) 50
Ring sideroblasts (%)
Median 53.5 46.5
Range 16–97 19–85
Karyotype
Tested (n) 87 25
Abnormal (n) 12 6
SF3B1 mutations (%) 88.3 82.7
Tested (n) 94 29
JAK2V617F mutations (%) 49.4 0.0
Tested (n) 95 29
MPL mutations (%) 1.1 0.0
Tested (n) 88 23
CALR mutations (%) 1 3.4
Tested (n) 95 29
Abbreviations: CALR, calreticulin; JAK2, Janus kinase 2; MPL, myeloproli-
ferative leukaemia; SF3B1, splicing factor 3B subunit 1; RARS, refractory
anaemia with ring sideroblasts; RARS-T, refractory anaemia with ring
sideroblasts and marked thrombocytosis; WBC, white blood cells.
Figure 1. Distribution of mutations in SF3B1, JAK2V617F, MPLW515L and CALR mutations in 95 RARS-T and 29 RARS. In RARS-T patients, SF3B1,
JAK2V617F,MPL and CALRmutations were observed in 88.3%, 49.4%, 1.1% and 1%, respectively. In RARS patients, SF3B1, JAK2V617F, MPL and CALR
mutations were observed in 82.7%, 0%, 0% and 3.4%, respectively.
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Among the 29 RARS, we also identiﬁed a single case with a CALR
mutation, which is consistent with a previous report.11
Surprisingly, the CALR-positive RARS-T patient also carried the
JAK2V617F mutation, which is to date, the ﬁrst double-mutant JAK2/
CALR ever described in RARS-T. Indeed, the CALR and JAK2V617F
mutations were described as mutually exclusive in the two recent
studies of 42300 haematologic cancers.10,11 However, another
group recently described a case of a JAK2/CALR double mutation
in PMF,15 which is in keeping with our results and proves
that these mutations coexist in rare cases. One can hypothesise
that this RARS-T patient with a JAK2/CALR mutation had two
different clones. However, owing to absence of frozen progenitor
cells, no clonogenic assay was feasible.
The two major types of CALR mutations are type 1 mutations
(52 bp deletion; c.1192_1143del) and type 2 mutations (5 bp
insertion; c.1154_1155insTTGTC).10 The CARL mutation described
in our RARS-T is a 10-bp deletion (1129–1138del), which is a rare
type of CALR exon 9 mutation that shifts the reading frame in a
similar way to all reported CALR mutations.
Finally, our study showed that CALR mutations are rare in MDS-
RS and thus do not explain the myeloproliferative part of RARS-T.
Approximately 40–50% of RARS-T are triple-negative for JAK2, MPL
and CALR mutations, indicating that further research is required to
explain the myeloproliferation in this rare MDS/MPN.
CONFLICT OF INTEREST
SS and TH declare part ownership of the MLL Munich Leukemia Laboratory. SJ is
employed by the MLL Munich Leukemia Laboratory. The remaining authors declare
no conﬂict of interest.
ACKNOWLEDGEMENTS
We would like to thank the medical doctors from the Haematology Department and
Laboratory of the University Hospital of Dijon, the Spanish Group of Hematological
Cytology (GECH). EL is grateful to Ms Marina Migeon for expert technical help and to
the Tumour Bank of the CHU of Bordeaux. We thank Sylvie Hermouet, medical doctor
at the University Hospital of Nantes, for reading the manuscript as well as Philip
Bastable for revising the manuscript. This work was supported by grants from the
association ‘Tulipes contre le cancer’ (Chaˆlon s/Saoˆne, Burgundy, France) and from
FEHH (Spain) and 2009 SGR 541 (Generalitat de Catalunya).
J Brose´us1,2,12,13,14, E Lippert3,4,12,13,14, AS Harutyunyan5,
S Jeromin6, E Zipperer7, L Florensa8,15, JD Milosevic5,
T Haferlach6, U Germing7, E Lun˜o9,15, S Schnittger6,13,
R Kralovics5,13 and F Girodon10,11,13,14
1Service d’He´matologie Biologique, University Hospital, Nancy, France;
2Inserm U954, Faculty of medicine, Nancy, France;
3Haematology laboratory, University Hospital, Bordeaux, France;
4Inserm U1035-Universite´ Bordeaux Segalen, Bordeaux, France;
5CeMM Research Center for Molecular Medicine of the Austria
Academy of Sciences, Vienna, Austria;
6MLL Munich Leukemia Laboratory, Munich, Germany;
7Department of Haematology, Oncology and Clinical Immunology,
Heinrich-Heine-Universita¨t, Du¨sseldorf, Germany;
8Laboratorio Citologia Hematolo`gica, Servicio Patologia, Hospital del
Mar, Barcelona, Spain;
9Servicio de Hematologı´a, Servicio de Salud del Principado de Asturias,
Oviedo, Spain;
10Haematology Laboratory, University Hospital, Dijon, France and
11Inserm U866, Faculty of Medicine Dijon, Dijon, France
E-mail: francois.girodon@chu-dijon.fr
12These authors contributed equally to this work.
13On behalf of MPN&MPNr-EuroNet (COST Action BM0902).
14On behalf of the French Intergroup of MPNs (FIM).
15On behalf of the Spanish Group of Hematological Cytology (GECH).
REFERENCES
1 Vardiman JW, Bennet JM, Bain BJ, Baumann I, Thiele J, Orazi A. Myelodysplastic/
myeloproliferative neoplasm, unclassiﬁable. In:). Swerdlow SH, Campo E,
Lee Harris N, Jaffe ES, Pileri SA, Stein H) (eds). WHO Classiﬁcation of Tumours of
Haematopoietic and Lymphoid Tissues. 4th edn. IARC: Lyon, France, 2008,
pp 85–86.
2 Renneville A, Quesnel B, Charpentier A, Terriou L, Crinquette A, Laı¨ JL et al.
High occurrence of JAK2 V617 mutation in refractory anemia with ringed
sideroblasts associated with marked thrombocytosis. Leukemia 2006; 20:
2067–2070.
3 Steensma DP, Caudill JS, Pardanani A, McClure RF, Lasho TL, Tefferi A. MPL W515
and JAK2 V617 mutation analysis in patients with refractory anemia with
ringed sideroblasts and an elevated platelet count. Haematologica 2006;
91(12 Suppl): ECR57.
4 Broseus J, Florensa L, Zipperer E, Schnittger S, Malcovati L, Richebourg S et al.
Clinical features and course of refractory anemia with ring sideroblasts associated
with marked thrombocytosis. Haematologica 2012; 97: 1036–1041.
5 Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M et al. MPL515
mutations in myeloproliferative and other myeloid disorders: a study of 1182
patients. Blood 2006; 108: 3472–3476.
6 Schnittger S, Bacher U, Haferlach C, Dengler R, Kro¨ber A, Kern W et al. Detection of
an MPLW515 mutation in a case with features of both essential thrombocythemia
and refractory anemia with ringed sideroblasts and thrombocytosis. Leukemia
2008; 22: 453–455.
7 Visconte V, Makishima H, Jankowska A, Szpurka H, Traina F, Jerez A et al. SF3B1,
a splicing factor is frequently mutated in refractory anemia with ring sideroblasts.
Leukemia 2012; 26: 542–545.
8 Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D et al.
Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med
2011; 365: 1384–1395.
9 Broseus J, Alpermann T, Wulfert M, Florensa Brichs L, Jeromin S, Lippert E et al.
Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for
survival in refractory anaemia with ring sideroblasts and marked thrombocytosis.
Leukemia 2013; 27: 1826–1831.
10 Klampﬂ T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD et al.
Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med
2013; 369: 2379–2390.
11 Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC et al. Somatic
CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J
Med 2013; 369: 2391–2405.
12 Lippert E, Boissinot M, Kralovics R, Girodon F, Dobo I, Praloran V et al. The JAK2-
V617F mutation is frequently present at diagnosis in patients with essential
thrombocythemia and polycythemia vera. Blood 2006; 108: 1865–1867.
13 Schnittger S, Bacher U, Haferlach C, Geer T, Mu¨ller P, Mittermu¨ller J et al. Detection
of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia
vera. Haematologica 2009; 94: 414–418.
14 Schnittger S, Bacher U, Haferlach C, Beelen D, Bojko P, Bu¨rkle D et al.
Characterization of 35 new cases with four different MPLW515 mutations
and essential thrombocytosis or primary myeloﬁbrosis. Haematologica 2009; 94:
141–144.
15 Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH et al. CALR vs
JAK2 vs MPL mutated or triple-negative myeloﬁbrosis: clinical, cytogenetic and
molecular comparisons. Leukemia 2014; e-pub ahead of print 21 January 2014;
doi:10.1038/leu.2014.3.
Letters to the Editor
1376
Leukemia (2014) 1341 – 1379 & 2014 Macmillan Publishers Limited
